MENORA MIVTACHIM HOLDINGS LTD.MENORA MIVTACHIM HOLDINGS LTD.

Institutional investor · Portfolio as of Q1 2024

SEC EDGAR SourceSEC Filings

Top Holdings88 positions

Checking export access…
Activity:
Stock
Shares
Value
Weight
Avg Buy
Est. P&L
Held
Conviction

MICROSOFT CORP

2.9M$1.2B9.0%$222.22+86.89%
21 qtrssince 2019-Q1
Increased
62

ALPHABET INC-CL A

5M$753.7M5.7%$99.76+50.16%
21 qtrssince 2019-Q1
Decreased
0

APPLE INC

3.8M$652.3M4.9%$125.64+35.02%
21 qtrssince 2019-Q1
Decreased
0

APPLIED MATERIALS INC

3.1M$629.2M4.7%$121.24+66.97%
13 qtrssince 2021-Q1
Decreased
0

META PLATFORMS INC-CLASS A

1.2M$592.5M4.4%$269.98+78.80%
16 qtrssince 2020-Q2
Increased
60

MASTERCARD INC - A

1M$488.8M3.7%$339.78+40.12%
13 qtrssince 2021-Q1
Increased
58

AMAZON.COM INC

2.7M$488.2M3.7%$115.36+56.37%
21 qtrssince 2019-Q1
Increased
58
TEVATEVA
ADR

TEVA PHARMACEUTICAL-SP ADR

28.1M$396.9M3.0%$9.33+51.22%
18 qtrssince 2019-Q4
Unchanged
0

NVIDIA CORP

434,521$392.6M2.9%$30.94+191.89%
21 qtrssince 2019-Q1
Increased
64

JPMORGAN CHASE & CO

1.7M$335.2M2.5%$146.11+31.34%
3 qtrssince 2023-Q3
Increased
57

UNITEDHEALTH GROUP INC

675,034$333.9M2.5%$472.66+0.97%
6 qtrssince 2022-Q4
Increased
57

WALMART INC

5.5M$331.4M2.5%$53.64+10.17%
21 qtrssince 2019-Q1
Increased
86

ABBOTT LABORATORIES

2.8M$321M2.4%$98.72+9.29%
15 qtrssince 2020-Q3
Increased
57
FLINFLIN
ETF

FRANKLIN TEMPLETON ETF TR

8.6M$318.6M2.4%$31.51+14.54%
4 qtrssince 2023-Q2
Decreased
0

ABBVIE INC

1.5M$280.4M2.1%$116.69+43.46%
16 qtrssince 2020-Q2
Increased
67

MICRON TECHNOLOGY INC

2.3M$274.8M2.1%$71.40+64.04%
17 qtrssince 2020-Q1
Increased
61

THERMO FISHER SCIENTIFIC INC

467,346$271.6M2.0%$408.69+41.42%
21 qtrssince 2019-Q1
Increased
58
EMXCEMXC
ETF

ISHARES MSCI EMR MRK EX CHNA

4.4M$252.3M1.9%$46.31+17.51%
5 qtrssince 2023-Q1
Decreased
0

OTIS WORLDWIDE CORP

2.4M$241.7M1.8%$61.04+55.23%
16 qtrssince 2020-Q2
Decreased
0

HOME DEPOT INC

597,003$229M1.7%$261.43+40.58%
21 qtrssince 2019-Q1
Decreased
0
$13.3B
AUM
88
Positions
Q1 2024
Filing
Rating · 2.0
Quarterly Portfolio Change
+12%Q4'22$5.9B+63%Q1'23$9.7B+12%Q2'23$10.8B+2%Q3'23$11B+8%Q4'23$11.9B+12%Q1'24$13.3B
Activity profile
$ moved · Q1'24
New6%Increased57%Decreased36%Exited2%
Composition
Equity vs derivatives
Equity100%Puts0%Calls0%
Holding period
Avg 2.4 years
<1Q3%1-4Q19%1-2Y28%2Y+49%

MENORA MIVTACHIM HOLDINGS LTD. manages $13.3B across 88 positions as of Q1 2024. Top holdings: MSFT (9.0%), GOOGL (5.7%), AAPL (4.9%). Fund DNA: Balanced Allocator. HoldingsIntel Rating: 2/5.0.

Q1 2024 Summary

Active quarter - 4 new positions, 13 exits, 38 increased. Top move: WMT (INCREASED, conviction 86). Portfolio: $13.3B across 88 positions.

Top holdings by portfolio weight

Total AUM$13B
MSFT9.00%
GOOGL5.66%
AAPL4.90%
AMAT4.72%
META4.45%
MA3.67%
AMZN3.66%
TEVA2.98%
NVDA2.95%
JPM2.52%
Other2.51%

Portfolio allocation by GICS sector

Sectors11
Technology31.13%
Healthcare12.49%
Unknown11.76%
Financial Services11.47%
Communication Services10.58%
Consumer Cyclical8.42%
Industrials4.04%
Consumer Defensive4.03%
Basic Materials3.01%
Real Estate1.96%
Other1.12%

Behavioral investing profile

Checking access…
Balanced Allocator- primarily Technology, Healthcare, Unknown
Compare DNA across all funds
7-dimension quality assessment
Below Average(2.0 / 5.0)
Track Record52
Conviction45
Concentration62
Checking access…

Position Outcomes

Best and worst performing positions by estimated return

Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.

Similar Funds

Funds with similar investing DNA

Accumulation Streaks

Positions with 2+ consecutive quarters of increases - persistent directional conviction.

Security
6Q
TEVATEVATEVA PHARMACEUTICAL-SP ADR
Q1 2025 Q2 2026+11.5M shares+$724.7M
5Q
KREKRESPDR SERIES TRUST
Q2 2025 Q2 2026+3.3M shares+$248M
4Q
QQQQQQINVESCO QQQ TRUST SERIES 1 CL USD INC
Q3 2025 Q2 2026+10,060 shares+$9.7M
Checking access…

Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used